Health Department’s dolutegravir plans hit stumbling block

Organisation: Position: Deadline Date: Location:

The Health Department’s plans to switch HIV patients to a cheaper pill containing dolutegravir have hit yet another stumbling block after measures instituted by the medicines regulator to warn women of its potential risks have unexpectedly scared them off. Business Day reports that more than six months after the government awarded supply contracts to pharmaceutical manufacturers, a mere 35,000 patients are on the new pills. The extremely low numbers have prompted the Health Department to ask the SA Health Products Regulatory Authority (Sahpra) to review its requirements, which are to be relaxed from this week.

“There has been a reluctance by prescribers and female patients to have to sign a form to access TLD (the new pill, which contains tenofovir, lamivudine and dolutegravir). Currently no other HIV treatment has this restriction,” said the health department’s acting director-general, Anban Pillay.

Projections in the supply contracts awarded to pharmaceutical manufacturers in July 2019 for TLD forecast the provision of 147m packs over three years, equivalent to about 4m patients a month.

Full Business Day report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.